S975
Clinical - Oligometastatic cancer
ESTRO 2026
multimodality treatment strategies or clinical trials. * IJ and EL equally contributed Keywords: Stereotactic body radiotherapy, atypical locations
colorectal (58%) cancer. Atypical sites were identified in 6% of patients (n=140), treated for 150 atypical lesions, most commonly in the adrenal glands, soft tissue, kidneys, peritoneum, and pleura. Thirty patients (21%) also received SBRT for a typical-site location. The median number of fractions was 5 (range, 1-12); median CTV volume 11 cc (0.2-252.0) and median CTV/ITV dose per fraction 9.6 Gy (4.0-23.7). No treatment-related grade ≥ 3 AEs occurred in patients with atypical sites. Local progression was observed in 14 of 140 patients (10%), with 1- and 3-year cumulative incidences of 3.6% (95% CI 1.3-7.7) and 10.2% (95% CI 5.5-16.7), respectively. For typical-site lesions, grade ≥ 3 AEs occurred in 1.4% of patients, and 1- and 3-year local progression incidences were 5.1% (95% CI 4.3- 6.1) and 11.5% (95% CI 10.0-13.0).
Poster Discussion 2735
Patient characteristics and treatment patterns in oligorecurrent prostate cancer treated on MR- Linac: insights from the international MOMENTUM study Kristine Skovly Nielsen 1,2 , Uffe Bernchou 1 , Carsten Brink 1 , Agon Olloni 1 , Helena M Verkooijen 3 , Marlies E Nowee 4 , Ananya Choudhury 5 , Shaista Hafeez 6 , Alison Tree 6 , Paulien Westhoff 7 , Paul Jeene 8 , Cihan Gani 9 , Filippo Alongi 10,11 , Michael Velec 12 , John Christodouleas 13 , William Hall 14 , Paul Renz 15 , Tine Schytte 1 1 Department of oncology, Odense University Hospital, Odense, Denmark. 2 Department of clinical research, University of Southern Denmark, Odense, Denmark. 3 Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands. 4 Department of Radiation Oncology, The Nederlands Cancer Institute, Amsterdam, Netherlands. 5 Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. 6 The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom. 7 Department of Radiation Oncology, Radbound University Medical Center, Nijmegen, Netherlands. 8 Radiotherapiegroep, ,, Deventer, Netherlands. 9 ., Universitätsklinikum, Tübingen, Germany. 10 Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella (VR), Italy. 11 University of Brescia, ., Brescia, Italy. 12 Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. 13 Elekta, ., Stockholm, Sweden. 14 Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, USA. 15 Allegheny health Network, ., Pittsburgh, USA Purpose/Objective: Oligorecurrent prostate cancer with nodal only recurrence after curative treatment, defines a new patient population without an established standard of care. Prospective registry studies offer an opportunity to generate evidence on treatment patterns and outcomes across institutions and countries, reflecting daily clinical practisce.The purpose of this study is to provide insights from a prospective international multicenter registry into patient characteristics, treatment patterns, and treatment outcomes across centers for oligorecurrent prostate cancer treated with local ablative MR-Linac–based radiotherapy. Material/Methods: Patients were included between February 2019 and
Conclusion: The anatomical distribution of oligometastases is mainly determined by the primary tumor type. Atypical oligometastases occur in 6% of patients and can be safely and effectively treated with SBRT, achieving outcomes comparable to those at typical sites. These patients should not be excluded from
Made with FlippingBook - Share PDF online